NVEC Just Posted 81% Revenue Growth and Nobody's Talking About It

Signal: BUY | Score: 67.25/100

NVE Corporation is a tiny semiconductor company that just delivered one of the best quarters you'll see anywhere in the market, and the stock is sitting 15% below its 52-week high. That gap between the results and the price is exactly where money gets made. This one deserves your attention today.

The Setup

NVEC is trading at $114.16, well off the $135 52-week high but way up from the $57.21 low set earlier this year. The RSI sits at 58.95, which means there's real momentum here without being overbought. That's a healthy setup for a continuation move. Momentum score comes in at 73.5 out of 100, the strongest component in the overall 67.25 composite. The stock doubled off its lows, consolidated, and now has a fresh earnings catalyst to fuel the next leg higher.

The Catalyst

On July 22, NVEC reported Q1 FY2027 earnings that were genuinely jaw-dropping for a company this size. Revenue surged 81% to $11.0 million. Product sales jumped 82%. Net income came in at $6.39 million, up 79% year over year. For context, this is a $549 million market cap company printing nearly $6.4 million in net income in a single quarter, with a 57.6% profit margin. That's elite-level profitability.

On top of the earnings beat, NVEC launched new wafer-level chip-scale sensors for implantable medical devices, including MRI-safe technology. This is a meaningful product expansion that moves NVEC beyond its defense-heavy base into a higher-growth medical end market. The board also declared another $1.00 per-share cash dividend payable August 31. At the current price, NVEC yields nearly 3%. You're getting paid to wait.

Bull Case

Valuation gap: The PEG ratio is 0.84. With 79-81% earnings growth, the stock is actually cheap relative to its growth rate, even at a 30x trailing P/E.
Medical device expansion: The new MRI-safe sensor line opens a secular growth market that defense alone couldn't provide.
Shareholder returns: NVEC pays consistent dividends and has minimal dilution. That capital discipline matters in a small cap.

Bear Case

Liquidity risk: This is a thinly traded micro-cap. Wide spreads and low volume can hurt your exit if sentiment turns.
Stretched forward multiple: The forward P/E of 40x assumes the growth rate holds. A single soft quarter could reprice this fast.

The Trade

Entry: $114.16
Target: $132 (near prior highs, roughly 15.6% upside)
Stop Loss: $101 (11.5% downside, below recent consolidation)
Risk/Reward: 1.4:1
Timeframe: 6 to 10 weeks, with next earnings on October 21

*This is one person's analysis, not financial advice. Always do your own research.*